Literature DB >> 26629158

Brain Natriuretic Peptide as the long-term cause of mortality in patients with cardiovascular disease: a retrospective cohort study.

Chunhong Zhang1, Dangsheng Huang1, Dong Shen1, Liwei Zhang1, Yumei Wang1, Hongyan Sun1, Yongjiang Ma1.   

Abstract

OBJECTIVE: To explore the influence of BNP (Brain Natriuretic Peptide) in plasma on the long-term cause of mortality and prognosis of patients with cardiovascular disease (CVD).
METHOD: We performed a retrospective cohort study of 276 inpatients that enrolled in our hospital from March 2003 to December 2004 and had a history of heart disease and received a BNP test. Kaplan-Meier survival curves with Log-Rank test were used to compare the survival rates among different levels of BNP (<100 ng/L, 101~1000 ng/L, 1001~5000 ng/L and >5000 ng/L). Cox proportional hazards regression models were used to estimate HRs and 95% CIs with adjustments for other covariance's. RESULT: After a median follow-up of 7 years, a total of 91 patients died of whom fifty were cardiogenic deaths and 41 were non-cardiogenic. The survival rates were of statistical significance (P=0.0000) between the different levels of BNP in the 4 groups, and the mortality rate increased gradually with the increase in BNP concentration. Multivariable Cox regression analysis showed that BNP levels were inversely associated with the survival rate in CVD patients (HR=0.24, 95% CI: 0.13~0.42). In addition, age and left ventricular ejection fraction values were also of statistical significance in the Cox regression model.
CONCLUSION: Our findings suggested that high Plasma BNP levels may have an adverse effect on the prognosis of patients with cardiovascular disease.

Entities:  

Keywords:  Brain natriuretic peptide; cardiovascular disease

Year:  2015        PMID: 26629158      PMCID: PMC4659046     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  10 in total

Review 1.  ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

Authors:  Kenneth Dickstein; Alain Cohen-Solal; Gerasimos Filippatos; John J V McMurray; Piotr Ponikowski; Philip Alexander Poole-Wilson; Anna Strömberg; Dirk J van Veldhuisen; Dan Atar; Arno W Hoes; Andre Keren; Alexandre Mebazaa; Markku Nieminen; Silvia Giuliana Priori; Karl Swedberg
Journal:  Eur J Heart Fail       Date:  2008-09-16       Impact factor: 15.534

2.  Direct comparison of B-type natriuretic peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data.

Authors:  Serge Masson; Roberto Latini; Inder S Anand; Tarcisio Vago; Laura Angelici; Simona Barlera; Emil D Missov; Aldo Clerico; Gianni Tognoni; Jay N Cohn
Journal:  Clin Chem       Date:  2006-06-15       Impact factor: 8.327

3.  B-type natriuretic peptide-guided heart failure therapy: A meta-analysis.

Authors:  Pramote Porapakkham; Pornwalee Porapakkham; Hendrik Zimmet; Baki Billah; Henry Krum
Journal:  Arch Intern Med       Date:  2010-03-22

Review 4.  Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing.

Authors:  Alexander G Semenov; Karina R Seferian
Journal:  Clin Chim Acta       Date:  2011-03-21       Impact factor: 3.786

Review 5.  Natriuretic peptide guided heart failure management.

Authors:  Asim A Mohammed; James L Januzzi
Journal:  Curr Clin Pharmacol       Date:  2009-05

Review 6.  Natriuretic peptides.

Authors:  Lori B Daniels; Alan S Maisel
Journal:  J Am Coll Cardiol       Date:  2007-12-18       Impact factor: 24.094

7.  How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification.

Authors:  Pompilio Faggiano; Roberto Valle; Nadia Aspromonte; Antonio D'Aloia; Giuseppe Di Tano; Sabrina Barro; Prospero Giovinazzo; Loredano Milani; Roberto Lorusso; Livio Dei Cas
Journal:  Int J Cardiol       Date:  2009-03-24       Impact factor: 4.164

Review 8.  Inpatient monitoring and prognostic importance of B-type natriuretic peptide.

Authors:  Nadia Aspromonte; Roberto Valle; William F Peacock; Marc Vanderheyden; Alan Maisel
Journal:  Congest Heart Fail       Date:  2008 Jul-Aug

9.  Plasma brain natriuretic peptide concentrations and the risk of cardiovascular events and death in general practice.

Authors:  Keizo Tsuchida; Kazuhiko Tanabe
Journal:  J Cardiol       Date:  2008-08-26       Impact factor: 3.159

Review 10.  Clinical applications of B-type natriuretic peptide (BNP) testing.

Authors:  M R Cowie; P Jourdain; A Maisel; U Dahlstrom; F Follath; R Isnard; A Luchner; T McDonagh; J Mair; M Nieminen; G Francis
Journal:  Eur Heart J       Date:  2003-10       Impact factor: 29.983

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.